1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Journal Article (3369)
  2. Meeting Abstract (1544)
  3. Review (164)
  4. Conference Paper (128)
  5. Book Section (124)
  6. Editorial (107)
  7. Research Letter (27)
  8. Miscellaneous (14)
  9. Book Whole (11)
  10. Guidelines (9)
  11. Correspondence (5)
Groups
  1. Center for Molecular Imaging and Biotechnology (5502)
  2. GSK Faculty (5304)
  3. Sloan Kettering Institute Faculty (3443)
  4. Tow Center for Developmental Oncology (TCDO) (2540)
  5. Department of Medicine (2432)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1823)

More Groups

People
  1. Richard O'Reilly (662)
  2. David Scheinberg (445)
  3. Ross Levine (426)
  4. Nai-Kong Cheung (419)
  5. Hedvig Hricak (387)
  6. Joan Massague (351)

More People

Years
  1. 2025 (1)
  2. 2024 (148)
  3. 2023 (248)
  4. 2022 (307)
  5. 2021 (289)
  6. 2020 (328)

More Years

Publications
  1. Blood (629)
  2. Cancer Research (188)
  3. Journal of Clinical Oncology (168)
  4. Journal of Nuclear Medicine (139)
  5. Biology of Blood and Marrow Transplantation (101)
  6. Proceedings of the National Academy of Sciences of the United States of America (95)

More Publications

Publishers
  1. American Society of Hematology (659)
  2. Nature Publishing Group (525)
  3. Elsevier Inc. (454)
  4. American Association for Cancer Research (366)
  5. Cell Press (354)
  6. Springer (202)

More Publishers

Results (5502)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAR T-cells followed by CD34-selected T-cell depleted (TCD) ALLO-HSCT is associated with low toxicity and favorable overall survival
    Meeting Abstract

    Fabrizio, V.; Boulad, F.; Cancio, M.; Margossian, S.; Mauguen, A.; Prockop, S.; Scaradavou, M.; Shah, N.; Spitzer, B.; Stieglitz, E.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors
    Meeting Abstract

    Yankelevich, M.; Modak, S.; Chu, R.; Lee, D. W.; Thakur, A.; Cheung, N. K. V.; Lum, L. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas
    Meeting Abstract

    Shoushtari, A. N.; Sanchez-Vega, F.; Kantheti, H.; Callahan, M. K.; Postow, M. A.; Barker, C. A.; Chatila, W. K.; Jonsson, P.; Ariyan, C. E.; Brady, M. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study
    Meeting Abstract

    Mora, J.; Kushner, B. H.; Flores, M. A.; Santa-Maria, V.; Garraus, M.; Basu, E. M.; Roberts, S. S.; Castaneda, A.; Gorostegui, M.; Cheung, N. K. V.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer
    Meeting Abstract

    Lai, W. C. V.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Ginsberg, M. S.; Kris, M. G.; Beras, A.; Rekhtman, N.; Poirier, J. T.; Hellmann, M. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM)
    Meeting Abstract

    Kushner, B. H.; Modak, S.; Basu, E. M.; Roberts, S. S.; Cheung, N. K. V.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy
    Meeting Abstract

    Greally, M.; Walch, H. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Schultz, N.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Differentiation and tissue-adaptation of type-2 innate lymphoid cells during helminth infection
    Meeting Abstract

    Lian, M.; Zeis, P.; Fan, X.; Symowski, C.; Gentek, R.; Bajenoff, M.; Rudensky, A. Y.; Voehringer, D.; Kastenmuller, W.; Grun, D.; more...
    European Journal of Immunology (2019)

    Fulltext@MSK | Save
  • Implantable nanosensor for non-invasive ovarian cancer biomarker detection with wearable interface
    Meeting Abstract

    Heller, D. A.; Williams, R. M.; Levine, D. A.
    Cancer Research (2019)

    Fulltext@MSK | Save